Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNEUMOSTEM Phase I/II in Preterm Infants for BPD Prevention
NCT02381366Phase 2Completed
- Sponsor
- MEDIPOST
- Start
- Mar 2015
- Primary completion
- Sep 2016
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of pneumostem in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by MEDIPOST. Primary endpoint: Number of participants with adverse reactions for 84 days after treatment. Started Mar 2015; status: completed.
02
Drugs
pneumostem
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT02381366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381366.